Figure 3

Mapping of HSA21 deletions in DNA and RNA from transchromosomic tumours. DNA and total RNA isolated from transchromosomic tumours were subjected to PCR or RT-PCR analyses, respectively, to determine the retention of each of 42 HSA21-specific markers in the transchromosome in the tumours. Shown on the right are the positions of markers relative to genes, and they correspond to the HSA21 STS markers analysed, listed on the left. cDNA markers are shown in bold text. PCR and RT-PCR analyses of DNA and RNA, respectively, isolated from D3 and 47-1 ES cell lines at the point of injection (first 2 columns, highlighted as red font) confirmed the full retention of HSA21 in 47-1 ES cells. No HSA21 markers were amplified in DNA or mRNA/cDNA from the D3 mouse control cell line. Markers in the 'INDI' regions that were commonly retained in all transchromosomic tumours are highlighted by green background. White box = no amplified product observed by agarose gel after 40 PCR cycles, black box = amplified product observed by agarose gel.